Chronic hepatitis B in Canada — monitoring, treatment, and liver-cancer surveillance

If you were born in India, China, the Philippines, Vietnam, Nigeria, or many other parts of Asia and sub-Saharan Africa, there is a meaningful chance you are carrying the hepatitis B virus without knowing it — and an even better chance that, if you do know, nobody has clearly explained what you actually need to do about it. Chronic hepatitis B is one of the most common serious infections in the world, and it is disproportionately common in exactly the communities that make up Canada's newcomer population. The good news is that it is manageable, often without any medication at all. The catch is that it needs to be watched, carefully and for life. This article explains what chronic hepatitis B means, how it should be monitored in Canada, when treatment is genuinely needed, why liver-cancer surveillance matters so much, and what to do about the people you live with.

Why newcomers from Asia and Africa should be screened

Hepatitis B is far more common in some parts of the world than others. In much of East Asia, South Asia, Southeast Asia, and sub-Saharan Africa, chronic hepatitis B affects a substantial share of the population — and most of those infections were acquired at birth or in early childhood, long before anyone was tested. Transmission from mother to baby, or between young children, produces a lifelong infection that usually causes no symptoms for decades. That is precisely why it goes unnoticed: you can feel completely well and still be chronically infected.

For Canadian newcomers from these regions, this has a simple practical consequence. If you have never been tested for hepatitis B, you should be — even if you feel fine, even if you have no risk factors you can think of. A single blood test (HBsAg, plus antibody markers) settles the question. Canadian and international guidance recommends screening people born in high-prevalence regions, and this is one of the most useful tests a newcomer can ask their family doctor — or a walk-in clinic — to order. If you have arrived without a family doctor, our guide to navigating BC healthcare without a family doctor covers where to start.

What "chronic hepatitis B" actually means

Hepatitis B is a viral infection of the liver. When an adult catches it, the immune system usually clears it within months. But when it is acquired at birth or in early childhood — the common route in high-prevalence regions — the body often cannot clear it, and the infection becomes lifelong. The formal definition of chronic hepatitis B is being HBsAg (hepatitis B surface antigen) positive for more than six months.

Here is the reassuring part, and the part that gets lost: most people with chronic hepatitis B are well and stay well. The virus lives quietly in the liver and, for many, causes little or no ongoing damage. You are not sick in any day-to-day sense. But the reason it still demands attention is that, in a proportion of people and often silently, the virus can drive liver inflammation, gradual scarring (fibrosis, then cirrhosis), and — importantly — liver cancer, even in people who never develop cirrhosis. The whole point of care is to catch those developments early, when something can be done, rather than late.

How chronic hepatitis B is monitored

Monitoring is the heart of hepatitis B care, and it revolves around a handful of tests that, together, tell your doctor which "phase" of infection you are in and whether anything is changing. Chronic hepatitis B is not one static state — it moves through phases over the years, and the right action depends on where you are.

The key tests

• HBsAg — the surface antigen. Positivity beyond six months is what defines chronic infection; its eventual loss is the best outcome.
• HBeAg and anti-HBe — the "e" antigen and its antibody. These markers help define the phase of infection and generally track with how actively the virus is replicating.
• HBV DNA (viral load) — a direct measure of how much virus is in the blood. This is one of the two most important numbers driving treatment decisions.
• ALT (and AST) — liver enzymes. A rising ALT signals that the liver is being inflamed and injured. Our companion guide on what elevated ALT and AST mean explains these numbers in detail.
• Fibrosis assessment (FibroScan) — a quick, painless scan that estimates how much scarring the liver has accumulated. It is the modern, non-invasive alternative to a biopsy for staging fibrosis and detecting cirrhosis.

Most people in a stable phase are monitored with blood work and imaging roughly every six months, sometimes annually — the interval depends on your phase, viral load, ALT trend, and fibrosis. It is also worth being screened for the things that make HBV worse, including fatty liver disease (NAFLD), which is common and can compound liver injury when it sits alongside chronic hepatitis B.

When treatment is — and isn't — needed

This is where a lot of anxiety lives, so it is worth being clear: a chronic hepatitis B diagnosis does not automatically mean you go on medication. Many people are in an inactive phase, with low viral load, normal ALT, and no significant fibrosis. For them, the correct treatment is careful monitoring — not antivirals. Starting medication in that situation would add cost and lifelong commitment without benefit.

The decision to treat is specialist-guided and rests mainly on three things working together: your HBV DNA (viral load), your ALT, and the degree of fibrosis on a FibroScan — weighted by your age and family history. When the virus is replicating actively, the liver is inflamed, or scarring is advancing, treatment is indicated to protect the liver and lower the long-term risk of cirrhosis and cancer. When it is indicated, the modern oral antivirals — tenofovir and entecavir — are highly effective, well tolerated, and taken as a single daily tablet, usually long term. They suppress the virus rather than eradicate it, which is exactly why monitoring continues even after treatment starts.

Liver-cancer surveillance — the part most often missed

If there is one message in this article to act on, it is this. Chronic hepatitis B increases the risk of liver cancer (hepatocellular carcinoma, or HCC) — and it can do so even in people who never develop cirrhosis, which makes HBV unusual among liver diseases. Because early liver cancer causes no symptoms, the only way to catch it while it is still treatable is to look for it deliberately, on a schedule.

For higher-risk patients, that means a liver ultrasound roughly every six months, often paired with an AFP (alpha-fetoprotein) blood test. Surveillance is generally recommended for anyone with cirrhosis, and for higher-risk groups without cirrhosis — including older adults, people with a family history of liver cancer, and people from high-prevalence regions such as much of Asia and sub-Saharan Africa. In practice this surveillance is frequently under-done: people are diagnosed with hepatitis B, told they are "a carrier," and then never placed on a 6-monthly ultrasound schedule at all. If that describes you, it is worth raising directly.

Protect the people around you — test and vaccinate contacts

Hepatitis B is transmissible, but it is also vaccine-preventable — and that combination means your diagnosis is an opportunity to protect the people you love. Household members and sexual partners should be tested to see whether they are already infected or immune, and anyone who is neither should be vaccinated. The hepatitis B vaccine is safe, effective, and widely available in Canada. For a family from a high-prevalence region, this single step can break a chain of transmission that may otherwise have run quietly through the household for years.

Babies born to mothers with hepatitis B need specific protection at birth, and pregnant women are routinely screened in Canada for exactly this reason — but the adults and older children in a household are the group most often overlooked. If you have chronic hepatitis B, make sure everyone you live with knows to get tested and, if appropriate, vaccinated.

For NRI families managing relatives with hepatitis B in India

Many of the people who come to Ginie Health are not asking only for themselves. They are the son in Surrey or the daughter in Brampton trying to make sense of a parent's hepatitis B reports from back home — a viral load in a different unit, a FibroScan from a hospital in Chandigarh or Delhi, a doctor's note in shorthand. Chronic hepatitis B is common across India, and the hepatology expertise at institutions like PGIMER Chandigarh and AIIMS is genuinely world-class and very high-volume — these are centres that manage chronic HBV, cirrhosis, and liver cancer every single day.

That is exactly the expertise Ginie Health is built around. Whether the patient is you in Canada or a parent in India, a hepatologist trained at PGIMER or AIIMS can review the full picture — HBV DNA, ALT trend, HBeAg status, FibroScan, and current surveillance — and tell you plainly whether treatment is indicated, what monitoring schedule to be on, and whether the liver-cancer surveillance is adequate. Hepatitis B is a condition where continuity and clear explanation matter enormously, and that is precisely the gap a written specialist opinion fills.

How a specialist opinion from Ginie Health works

Here is the service in plain terms. You upload your hepatitis B results — HBsAg, HBeAg/anti-HBe, HBV DNA, ALT, any FibroScan or ultrasound reports — and describe your history. Within 6 hours, for $45 CAD, you receive a written clinical opinion from a hepatologist or gastroenterologist trained at PGIMER Chandigarh or AIIMS. The opinion tells you what your results mean, whether antiviral treatment is likely to be indicated, exactly what monitoring and liver-cancer surveillance schedule you should be on, and how to get your contacts tested and vaccinated.

It does not replace your Canadian hepatologist or family doctor — it makes every interaction with them count, and it gives you the confidence to ask for the FibroScan and the 6-monthly ultrasound if you are not already getting them. If you would rather talk it through, a live video consultation is available for $75 CAD. No referral is required for either.